SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Based is a financial superapp built on Hyperliquid that lets users trade crypto, equities, and commodities from a single interface, fund accounts directly from bank accounts or credit cards, and spend balances at over 100 million merchants worldwide using a Visa Platinum card that converts at the point of sale with no separate off-ramp required. The platform operates across web, iOS, Android, and desktop with one account, and includes features like curated Launchpools for early project access and AI-native wallets for autonomous trading and risk monitoring.

Based Token

Based is trending as investors debate its utility-focused 'crypto super app' model against concerns over volatility and potential manipulation common in smaller market cap assets. The community is actively discussing the platform's app functionality and potential for future growth while navigating aggressive price swings and frequent short-term trading patterns.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is seeing heightened volatility as markets digest TSMC's comments regarding the high cost of next-generation High-NA EUV machinery, leading some investors to debate the timeline for adoption versus the company's entrenched lithography monopoly. Despite the pullback, the community remains intensely focused on the stock's role as the indispensable bottleneck for AI infrastructure, with many traders framing the price dip as a long-term accumulation opportunity.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as investors debate the potential for a buyout following the company's decision to shutter its internal discovery unit and focus on capital-efficient external innovation. The community is actively discussing the stock's future in light of institutional accumulation, ongoing management decisions, and the upcoming data readouts for its HAE drug pipeline.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending following the announcement of an upcoming FDA advisory committee meeting for Deramiocel and the release of positive five-year clinical data. The community is actively debating whether this committee serves as a pathway for broader regulatory approval or represents a source of renewed uncertainty regarding the path to commercialization.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility and heavy trading volume as investors weigh the company's long-term AI-driven infrastructure transition against ongoing concerns regarding its legacy business decline and high debt. The community is actively debating the potential of new private connectivity deals and strategic acquisitions to trigger a revenue inflection, with many expressing frustration over lack of transparency while others view the current price action as a shakeout for a long-term turnaround.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMC is trending as the central foundry bottleneck for the AI supply chain, with institutional investors increasingly focused on its massive capital expenditure for advanced nodes and persistent capacity constraints that continue to drive aggressive long-term growth. Community discussion is heavily centered on the company's pricing power, its structural role in enabling NVIDIA and other hyperscalers, and debates over managing geopolitical risks amidst relentless demand for advanced semiconductor manufacturing.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the recent double-digit decline represents a structural breakdown or a significant accumulation opportunity following a guidance adjustment and accelerated share repurchase program. While some market participants express frustration over persistent selling pressure, many community members are aggressively loading shares, viewing the current valuation as disconnected from long-term fundamentals and potential M&A catalysts.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is capturing significant market attention as it decouples from broader crypto trends, driven by its unique model that funnels platform trading fees into token buybacks. Community discussions are heavily focused on the project's institutional-grade infrastructure and its emergence as a decentralized alternative to traditional financial exchanges.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is facing heavy downward pressure and significant investor frustration as the stock continues to trade at a steep discount to its net asset value, despite recent inclusion in the Russell 1000 index. While the community is actively debating the company's management and the impact of frequent stock issuance to acquire Ethereum, many are highlighting the stock's role as a leveraged play on institutional crypto adoption and potential future regulatory clarity.

Flutter Entertainment Plc engages in the business of online betting and gaming. It operates through the following segments: UK and Ireland, Australia, International, and US. The UK and Ireland segment includes the operations of Sky Betting and Gaming, Paddy Power, Betfair, and tombola. The Australia segment focuses on sports betting services provided to Australian customers online. The International segment relates to poker, casino, rummy, lottery, and sports betting. The US segment includes sports betting, daily fantasy sports, and gaming services. The company was founded in 1988 and is headquartered in New York, NY.

Flutter Entertainment Plc

Flutter Entertainment is experiencing heightened investor attention as market participants weigh the impact of rising competition from prediction markets against the company's dominant U.S. market share and international diversification. Community discussion remains focused on whether recent price volatility presents a buying opportunity or a structural shift, with traders closely monitoring upcoming earnings and seasonal sports cycles as key catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

American Well (AMWL) Moves 9.4% Higher: Will This Strength Last?

American Well (AMWL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics

TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer 10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies...

TXG Gains From Proteintech Deal, Expands Multiomics Capabilities

10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.

Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group PR Newswire PLEASANTON, Calif., June 9, 2026 Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026...

10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.

Key PointsCEO Serge Saxonov sold 28,893 shares for a total of ~$709,000 across two open-market transactions completed by May 26, 2026...

This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%

Key PointsQuantedge Capital added 212,600 shares of 10x Genomics in the first quarter; the estimated transaction value was $4.25 million based on quarterly average pricing...

10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up

TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.

10x Genomics (TXG) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

10x Genomics Inc - Ordinary Shares - Class A

10x Genomics Partners With Anthropic To Bring AI Tools For Researchers

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.24	--	--	N/A
Q1 '26	-$0.28	-$0.10	63.65%	BEAT
Q4 '25	-$0.20	-$0.13	35.89%	BEAT
Q3 '25	-$0.29	-$0.22	23.71%	BEAT
Q2 '25	-$0.37	$0.28	175.35%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

TXG10x Genomics Inc - Ordinary Shares - Class A

Upcoming Earnings: Q2 '26

Historical Earnings

Latest TXG News